TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06406803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary energy restriction
Description: Patients enrolled in the dietary energy restriction group will reach an energy deficit of 40% only through reduced dietary intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily exercise
Description: Patients in the daily exercise group will reach an energy deficit of 40% through reduced dietary intake and increased physical activity (exercise).
Study: NCT05692310

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: placing a standard central venous line
Description: Patients will benefit from the technique of central venous line placement by conventional ultrasound.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placement of a central venous line using an ultraportable ultrasound device
Description: Patients will have a central venous line placed using an ultraportable ultrasound device
Study: NCT05768243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: hyaluronic acid is used as an adjunctive treatment to scaling and root planing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: red injectable platelet rich fibrin (i-prf)
Description: injecting red i-prf into the pocket after scaling and root planing
Study: NCT04489667

Intervention type: OTHER
Group type: OTHER
Intervention: +STEP Implementation
Description: All patients receiving care at five RWHAP-funded clinics will receive the intervention (+STEP), in which patient-reported outcomes (PROs) on mental health and substance use disorder (SUD) will be integrated into routine care, targeted training will be provided for frontline clinicians on best practices for mental health and SUD treatment, and telemedicine for mental health and SUD will be offered to patients in need of expanded access to services.
Study: NCT05569850

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brushing
Description: Brushing the teeth 2x a day for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brushing
Description: Brushing the teeth 2x a day for 4 weeks.
Study: NCT05406258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Self-Catheterization Mirror
Description: Following training, participants will have a modified mirror available for self-catheterization, as well as a standard, hospital-provided mirror. They will record the mirror used, position, and time for self-catheterization. They will also complete the System Usability Scale for each mirror related to self-operation and user satisfaction.
Study: NCT05187793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olokizumab
Description: Olokizumab, 128 mg, solution for subcutaneous administration 160 mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy
Description: Standard treatment including:~* Baricitinib, 4 mg, film coated tablets~* Favipiravir, 200 mg, film coated tablets~* Dexamethasone IV or IM OR Methylprednisolone IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy
Description: Standard treatment including:~* Baricitinib, 4 mg, film coated tablets~* Favipiravir, 200 mg, film coated tablets~* Dexamethasone IV or IM OR Methylprednisolone IV
Study: NCT04836728

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CIK cell injection
Description: CIK cells, more than 1x10\^10 (10 billion ), intravenous infusion,d14; Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Injection
Description: Sintilimab Injection intravenous infusion 200mg d1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab Injection
Description: Sintilimab Injection intravenous infusion 200mg d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed intravenous infusion 500mg/m2 d2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed intravenous infusion 500mg/m2 d2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin paclitaxel
Description: Albumin paclitaxel intravenous infusion 260mg/m2 d2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin paclitaxel
Description: Albumin paclitaxel intravenous infusion 260mg/m2 d2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin intravenous infusion AUC5 d2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin intravenous infusion AUC5 d2
Study: NCT04666233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection
Description: The team will perform neonatal resuscitation with PPE for the prevention of SARS-Cov-2 infection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection
Description: The team will perform neonatal resuscitation without PPE for the prevention of SARS-Cov-2 infection
Study: NCT05400954

Intervention type: PROCEDURE
Intervention: Breast reconstruction with silicone breast implant
Description: (i) mastectomy followed by immediate implant-based reconstruction, (ii) mastectomy followed by implant-based reconstruction at a later stage and (iii) latissimus dorsi flap reconstruction with a silicone breast implant.

Intervention type: PROCEDURE
Intervention: Breast conserving surgery/Mastectomy/Autologous reconstruction
Description: (iv) simple mastectomy without reconstruction, (v) autologous reconstruction and (vi) breast conserving surgery,

Intervention type: PROCEDURE
Intervention: Breast Augmentation
Description: (vii) cosmetic augmentation with silicone breast implants
Study: NCT05324995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multimodal Drug
Description: The Multimodal Drug group received morphine, epinephrine, and ketorolac (n=48), The epinephrine group (placebo group) (n=49) received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary,and the celecoxib group(control group)(n=49) recieved 400mg celecoxib orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epinephrine
Description: The second group received 300 mcg epinephrine (1:1000) (DarouPakhsh, Tehran, Iran) peri-articulary

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: The third group administered celecoxib (200 mg) orally immediately before the surgery
Study: NCT04945785

Intervention type: OTHER
Intervention: No intervention
Description: no intervention

Intervention type: OTHER
Intervention: No intervention
Description: no intervention
Study: NCT05275764

Intervention type: PROCEDURE
Intervention: primary or secondary intraocular lens implantation surgery
Description: primary or secondary intraocular lens implantation surgery

Intervention type: PROCEDURE
Intervention: primary or secondary intraocular lens implantation surgery
Description: primary or secondary intraocular lens implantation surgery
Study: NCT05120947

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 42 Gy Radiation Therapy
Description: Radiation Therapy: Dose per fraction of 4.2 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 39 Gy Radiation Therapy
Description: Radiation Therapy: Dose per fraction of 4.875 Gy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 32.5 Gy Radiation Therapy
Description: Radiation Therapy: Dose per fraction of 6.5 Gy.
Study: NCT06073639

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autogenous dentin graft
Description: Dentin graft is made from the participant extracted tooth by using Kometa Smart Dentin Grinder
Study: NCT04791059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-ketamine
Description: S-ketamine 50 mg is included in the mixture for patient-controlled analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 200 microgram is included in the mixture for patient-controlled analgesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sufentanil
Description: Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil
Description: Sufentanil 4 microgram/kg (maximum 250 microgram) is included in the mixture for patient-controlled analgesia.
Study: NCT04969848

Intervention type: OTHER
Intervention: Wearable sensor
Description: IMU sensor (as part of eMSGait device) worn at the hip during T25FW
Study: NCT06077370

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: deep TMS
Description: Deep Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TMS
Description: Sham Transcranial magnetic stimulation on anterior Cingulate cortex and medial prefrontal cortex. 20 Hz.
Study: NCT06061107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Handbook for Geriatric Prearranged Medical Care Consultation
Description: The experimental group utilized a cartoon version of the Advance Care Consultation for the Elderly manual to facilitate the ACP process, which encompassed three components: an introduction to ACP, an overview of terminal medical care, and a discussion about the participants' preferences for their past, current, and future required medical care. There are three measurement time points: pre-test, two weeks after intervention, and one month after intervention.
Study: NCT06505525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-articular reconstruction with the Anterolateral Ligament
Description: Anatomical ACL reconstruction combined with extra-articular reconstruction with the Anterolateral Ligament

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extra-articular reconstruction with the Anterolateral Ligament
Description: Anatomical ACL reconstruction combined with extra-articular reconstruction with the Anterolateral Ligament
Study: NCT06389994

Intervention type: DEVICE
Intervention: Esophageal String Test
Description: The EnteroTracker® capsule is supplied in pouches, each pouch containing a single capsule. The device is comprised of an ingestible capsule that contains a weighted ball and a highly absorbent nylon string. The looped portion of the string is secured externally to the patient's cheek and the rest of the capsule is swallowed by the patient.
Study: NCT04923958

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Novel mycobacterial culture techniques
Description: We will evaluate tests intended to make culture more sensitive, faster, and have less contamination.
Study: NCT04529954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid delivered to ICV
Description: Valproic Acid delivered to ICV via an implantable pump and catheter system
Study: NCT05579002

Intervention type: OTHER
Intervention: Questionnaires and tests
Description: Application of three questionnaires:~1. Canadian Occupational Performance Measure (CORM),~2. a version of the Disabilities of the Arm Shoulder and Hand (DASH) modified for the child~3. a questionnaire developed by CEREFAM~   * Two analytical and functional tests:~1) the Action Research Arm Test (ARAT) 2) modified 400-point assessment.
Study: NCT04923958

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Novel sputum smear microscopy techniques
Description: We will evaluate new staining techniques or visualization methods to increase the sensitivity of smear microscopy.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sputum-based molecular assays
Description: We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tongue swab-based molecular assays
Description: We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urine LAM assays
Description: We will evaluate urine LAM assays incorporating techniques such as analyte concentration, higher sensitivity or specificity antibodies, or enhanced visualization to improve LAM detection.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood-based host immune response assays
Description: We will evaluate assays measuring host immune response parameters intended for use at near point of care or point of care.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breath-based assays
Description: We will evaluate assays assessing volatile organic compounds or exhaled breath condensate for near point of care of point of care detection of TB.
Study: NCT04675294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: evorpacept
Description: IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: IV Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pembrolizumab
Description: IV Q3W
Study: NCT04923958

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial intelligence-based digital health tools
Description: We will evaluate AI-based algorithms evaluating images (chest x-ray, ultrasound) or sounds (cough sounds, lung sounds) including an Infrasound-to-ultrasound e-stethoscope (Level 42 AI, USA).
Study: NCT06021015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）
Description: Irinotecan and polyvinyl alcohol sodium acrylate embolization microspheres（Unipearls®）

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan and HepaSphere Microspheres
Description: Irinotecan and HepaSphere Microspheres
Study: NCT05584644

Intervention type: DRUG
Intervention: Palbociclib plus hormonal treatment - first line treatment
Description: Palbociclib plus hormonal treatment

Intervention type: DRUG
Intervention: Palbociclib plus hormonal treatment - second line treatment
Description: Palbociclib plus hormonal treatment
Study: NCT05322642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UPA
Description: UP-A is divided into five main treatment modules and three optional modules. The UP-A seek to positively affect how adolescents with anxiety and/ or depression experiences, think about, and respond to a broad range of negative and positive emotions, rather than disorder-specific emotions (e.g., fear, sadness).
Study: NCT04923958

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Phage-based assays
Description: We will evaluate assays using phages to lyse mycobacterial cells for detection of DNA or antigens.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cartridge-based molecular assays for detecting drug resistance
Description: We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
Study: NCT05322642

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control condition (Progressive Relaxation Training)
Description: Progressive Relaxation Training (Bernstein and Borkovec) program is divided in ten sessions. Relaxation training often is used in behavior therapy as a means to reduce anxiety, tension, and stress. The goal is to release tension from your muscles, while helping you recognize what that tension feels like.
Study: NCT06053736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REVIVE Contact Lens
Description: REVIVE Contact Lens
Study: NCT04796298

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ballistic Hamstring Stretching
Description: Athletes were asked to reach the floor in the BS group by leaning over in the standing posture without knee flexion. When they feel the tension in hamstring muscle groups, athletes were requested to make small rebounding motion at degrees between 3°-5° for half a minute.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hamstring Extender Exercise
Description: Athletes were asked to applied 12 repetitions and 3 sets of hamstring extender exercise. Firstly athlete lies on his/her back. Then, athlete is asked to do 90 degrees of knee and hip flexion at the same time. Finally, the person is expected to perform slow repetitive knee extension to the point of maximal possible extension.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesiotape
Description: Kinesio tape is applied on the hamstring muscle with a Y shape and %25 tension force.
Study: NCT05547841

Intervention type: DEVICE
Intervention: Echocardiography acquisition
Description: Echocardiography examination of all participants using PHILIPS. Time points for heart image acquisition in pregnant women: As per the Guidelines for Pre-pregnancy and Pregnancy Health Care (2018) formulated by the Obstetrics Group of the Gynecology Branch of the Chinese Medical Association, a total of six echocardiographic examinations will be performed in the first trimester (11-14 weeks of gestation), the second trimester(20-24 weeks of gestation), the third trimester (29-32 weeks of gestation), prenatal term (37-40 weeks of gestation), 6 weeks and 3-6 months after delivery. Time points for fetal heart image acquisition: Fetal heart images will be collected in the second trimester(20 to 24 weeks of gestation).
Study: NCT04923958

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sequencing-based assays for detecting drug resistance
Description: We will evaluate targeted and whole genome sequencing assays.
Study: NCT06172829

Intervention type: DEVICE
Intervention: Advantage MX Module
Description: no intervention will be provided.

Intervention type: DEVICE
Intervention: Advantage MX Module
Description: no intervention will be provided.

Intervention type: DEVICE
Intervention: Advantage MX Module
Description: no intervention will be provided.

Intervention type: DEVICE
Intervention: Advantage MX Module
Description: no intervention will be provided.

Intervention type: DEVICE
Intervention: Advantage MX Module
Description: no intervention will be provided.
Study: NCT05151549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: 200mg/3weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin or Carboplatin
Description: Cisplatin (40mg/m²), every week Carboplatin(AUC 2)
Study: NCT05985616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Resistance Training
Description: High intensity resistance training will be performed 3 times a day for sixteen weeks
Study: NCT05568966

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Venous blood draw
Description: Venepuncture to draw up to 24mL of venous blood.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fingerstick
Description: Capillary blood draw
Study: NCT06188403

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthognathic surgery (lefort1)
Description: Lefort 1 osteotomy to reposition the maxilla using two different techniques to achieve more accurate results , one with guide for cutting and placing pre bent stock plates and the other method using custom titanium plates with guide for cutting and placing the plate

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthognathic surgery (lefort1)
Description: Lefort 1 osteotomy to reposition the maxilla using two different techniques to achieve more accurate results , one with guide for cutting and placing pre bent stock plates and the other method using custom titanium plates with guide for cutting and placing the plate
Study: NCT05838586

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prolonged SB
Description: 4 hours of prolonged SB

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SB broken 1
Description: 4 hours of SB broken up by 5 minutes of self-paced walking every hour

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SB broken 2
Description: 4 hours of SB with one 20-minute bout of self-paced walking
Study: NCT05960656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: A medication used in the management and treatment of type 2 diabetes mellitus. It is in the sodium-glucose co-transporter (SGLT-2) class of medications.
Study: NCT04946123

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-carnitine+Selenium
Description: Supplementation with L-carnitine and Selenium
Study: NCT05394987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Prescription of refractive error correction in spectacles. Refractive error to be determined as part of standard optometric eye exam (performed by registered optometrist).~Guidelines for optical correction for the prescription of the study spectacles (based on Pediatric Eye Disease Investigator Group \[PEDIG\] amblyopia clinical trial protocols): Hypermetropia: not undercorrected by \>+1.50D spherical equivalent and the reduction in plus sphere must be identical between the two eyes. Anisometropia: full correction of the anisometropic difference. Astigmatism: cylinder power in each eye should be within ≤±0.50D of fully correcting the astigmatism for each eye. If cylinder power is ≥1.00D, the prescribed axis in both eyes should be within ≤±6 deg of the cycloplegic refraction axis.~Appropriate refractive error correction will be prescribed. Participants will be instructed to wear the optical correction full-time (i.e., \>50% of waking hours) for the duration of the study.
Study: NCT04847557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT05729386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC2129A(Period 1)
Description: Linagliptin and Metformin Hydrochloride Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)
Description: Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC2129A(Period 2)
Description: Linagliptin and Metformin Hydrochloride Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)
Description: Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
Study: NCT06032247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise program- UL
Description: Unilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include single-leg squats, split squats, single-leg deadlifts, single-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance exercise program- BL
Description: Bilateral group:~Exercise sessions supervised by an exercise professional. Exercises will include double-leg squats, double-leg deadlifts, double-leg leg extensions, etc. Repetition range and volume (sets performed) will target strength and hypertrophy range with linear periodization utilized to ensure progression.